2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759-69.

In the vast landscape of antibody drug development, the interaction between IgG and neonatal Fc receptor ( FcRn ) stands as an undeniable cornerstone. This interaction profoundly shapes the ...

Anti-FcRn antibody therapeutics reduce IgG levels via binding of the neonatal Fc receptor (FcRn), inhibiting IgG recycling and lowering circulating IgG levels. The ability of CYR212 to deplete ...

Nipocalimab is one of a newer class of autoimmune drugs known as FcRn antibodies that was the key asset in J&J's $6.5 billion acquisition of Momenta Pharmaceuticals in 2020. The company is ...

Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in ...

Arteriviruses target immune cells and cells lining blood vessels, both containing the FcRn receptor, which also transports ...

(NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody ... to bind to the FcRn receptor with more ...